Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients

R. Fogari, A. Zoppi, I. Ferrari, A. Mugellini, P. Preti, P. Lazzari, G. Derosa

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The aim of this study was to compare the effect of telmisartan and eprosartan on insulin sensitivity in overweight hypertensive patients. Fifty overweight (BMI≥25 and 2) outpatients, aged 41-65 years, with mild to moderate hypertension [systolic blood pressure (SBP) >140 and diastolic blood pressure (DBP) ≥90 and ≤110mmHg], after a 4-week placebo period, were randomized to receive telmisartan 80mg or eprosartan 600mg for 8 weeks. Following another 4-week placebo period, patients were crossed to the alternative regimen for further 8 weeks. At the end of each placebo and active treatment period, blood pressure (BP), insulin sensitivity (by euglycemic hyperinsulinemic clamp), fasting plasma glucose (FPG), insulin (FPI), total cholesterol (TC), LDL-C, HDL-C, and triglycerides (Tg) were evaluated. Insulin sensitivity was expressed as the amount of glucose infused during the last 30min (glucose infusion rate, GIR) in μmol/min/kg. Both telmisartan and eprosartan significantly reduced SBP/DBP values (by a mean of 19.4/13.3mmHg and 17.9/12.1mmHg respectively, all p

Original languageEnglish
Pages (from-to)893-898
Number of pages6
JournalHormone and Metabolic Research
Volume41
Issue number12
DOIs
Publication statusPublished - 2009

Fingerprint

Blood pressure
Insulin Resistance
Insulin
Blood Pressure
Glucose
Therapeutics
Placebos
Clamping devices
LDL Cholesterol
Triglycerides
telmisartan
eprosartan
Glucose Clamp Technique
Plasmas
Fasting
Outpatients
Hypertension

Keywords

  • AT 1 blockers
  • Body weight
  • Hyperinsulinemic clamp
  • Hypertension
  • Insulin resistance
  • Sartans

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{e2e91a9429334511a34c34972f959c37,
title = "Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients",
abstract = "The aim of this study was to compare the effect of telmisartan and eprosartan on insulin sensitivity in overweight hypertensive patients. Fifty overweight (BMI≥25 and 2) outpatients, aged 41-65 years, with mild to moderate hypertension [systolic blood pressure (SBP) >140 and diastolic blood pressure (DBP) ≥90 and ≤110mmHg], after a 4-week placebo period, were randomized to receive telmisartan 80mg or eprosartan 600mg for 8 weeks. Following another 4-week placebo period, patients were crossed to the alternative regimen for further 8 weeks. At the end of each placebo and active treatment period, blood pressure (BP), insulin sensitivity (by euglycemic hyperinsulinemic clamp), fasting plasma glucose (FPG), insulin (FPI), total cholesterol (TC), LDL-C, HDL-C, and triglycerides (Tg) were evaluated. Insulin sensitivity was expressed as the amount of glucose infused during the last 30min (glucose infusion rate, GIR) in μmol/min/kg. Both telmisartan and eprosartan significantly reduced SBP/DBP values (by a mean of 19.4/13.3mmHg and 17.9/12.1mmHg respectively, all p",
keywords = "AT 1 blockers, Body weight, Hyperinsulinemic clamp, Hypertension, Insulin resistance, Sartans",
author = "R. Fogari and A. Zoppi and I. Ferrari and A. Mugellini and P. Preti and P. Lazzari and G. Derosa",
year = "2009",
doi = "10.1055/s-0029-1237359",
language = "English",
volume = "41",
pages = "893--898",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "12",

}

TY - JOUR

T1 - Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients

AU - Fogari, R.

AU - Zoppi, A.

AU - Ferrari, I.

AU - Mugellini, A.

AU - Preti, P.

AU - Lazzari, P.

AU - Derosa, G.

PY - 2009

Y1 - 2009

N2 - The aim of this study was to compare the effect of telmisartan and eprosartan on insulin sensitivity in overweight hypertensive patients. Fifty overweight (BMI≥25 and 2) outpatients, aged 41-65 years, with mild to moderate hypertension [systolic blood pressure (SBP) >140 and diastolic blood pressure (DBP) ≥90 and ≤110mmHg], after a 4-week placebo period, were randomized to receive telmisartan 80mg or eprosartan 600mg for 8 weeks. Following another 4-week placebo period, patients were crossed to the alternative regimen for further 8 weeks. At the end of each placebo and active treatment period, blood pressure (BP), insulin sensitivity (by euglycemic hyperinsulinemic clamp), fasting plasma glucose (FPG), insulin (FPI), total cholesterol (TC), LDL-C, HDL-C, and triglycerides (Tg) were evaluated. Insulin sensitivity was expressed as the amount of glucose infused during the last 30min (glucose infusion rate, GIR) in μmol/min/kg. Both telmisartan and eprosartan significantly reduced SBP/DBP values (by a mean of 19.4/13.3mmHg and 17.9/12.1mmHg respectively, all p

AB - The aim of this study was to compare the effect of telmisartan and eprosartan on insulin sensitivity in overweight hypertensive patients. Fifty overweight (BMI≥25 and 2) outpatients, aged 41-65 years, with mild to moderate hypertension [systolic blood pressure (SBP) >140 and diastolic blood pressure (DBP) ≥90 and ≤110mmHg], after a 4-week placebo period, were randomized to receive telmisartan 80mg or eprosartan 600mg for 8 weeks. Following another 4-week placebo period, patients were crossed to the alternative regimen for further 8 weeks. At the end of each placebo and active treatment period, blood pressure (BP), insulin sensitivity (by euglycemic hyperinsulinemic clamp), fasting plasma glucose (FPG), insulin (FPI), total cholesterol (TC), LDL-C, HDL-C, and triglycerides (Tg) were evaluated. Insulin sensitivity was expressed as the amount of glucose infused during the last 30min (glucose infusion rate, GIR) in μmol/min/kg. Both telmisartan and eprosartan significantly reduced SBP/DBP values (by a mean of 19.4/13.3mmHg and 17.9/12.1mmHg respectively, all p

KW - AT 1 blockers

KW - Body weight

KW - Hyperinsulinemic clamp

KW - Hypertension

KW - Insulin resistance

KW - Sartans

UR - http://www.scopus.com/inward/record.url?scp=71849091557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849091557&partnerID=8YFLogxK

U2 - 10.1055/s-0029-1237359

DO - 10.1055/s-0029-1237359

M3 - Article

VL - 41

SP - 893

EP - 898

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 12

ER -